BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient
Status:
Not yet recruiting
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
The purpose of the study is to demonstrate the Pharmacodynamic bioequivalence of the test
product to the reference product in adult patient with Asthma
Phase:
Phase 3
Details
Lead Sponsor:
Cipla Ltd.
Treatments:
Budesonide Budesonide, Formoterol Fumarate Drug Combination Formoterol Fumarate